Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease

0Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

We present results from clinical studies on plasma infusion done in the late 1970s in patients with hypogammaglobulinemia in which we documented the short half-life of both total and allergen-specific IgE in serum. The development of specific allergic sensitization in the skin of those patients followed by the gradual decrease in sensitization over 50 days was also documented. The data are included here along with a discussion of the existing literature about the half-life of IgE in both the circulation and skin. This rostrum reinterprets the earlier clinical studies in light of new insights and mechanisms that could explain the rapid removal of IgE from the circulation. These mechanisms have clinical implications that relate to the increasing use of anti-IgE mAbs for the treatment of allergic disease.

Cite

CITATION STYLE

APA

Lawrence, M. G., Woodfolk, J. A., Schuyler, A. J., Stillman, L. C., Chapman, M. D., & Platts-Mills, T. A. E. (2017). Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease. Journal of Allergy and Clinical Immunology, 139(2), 422-428.e4. https://doi.org/10.1016/j.jaci.2016.04.056

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free